Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609369 · ClinicalTrials.gov registry record · Phase 2
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
A Phase 2 study of Insomnia and Tobacco Use, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
- 2
- Study locations
NCT06609369 is a Phase 2 study of Insomnia and Tobacco Use that is actively recruiting participants, run by Yale University. The registered enrollment target is 114 participants, below the 169-participant average among 151 other Insomnia trials with a reported enrollment target (33% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06609369, a Phase 2 study of Insomnia and Tobacco Use, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study aims to investigate whether behavioral interventions promote cessation in adult smokers by ameliorating negative emotions and improving self-control and identify the neural markers of these effects.
Conditions Studied
Interventions
- BEHAVIORAL Experimental health intervention
- DRUG Varenicline
Study Locations (2)
Connecticut
- Connecticut Mental Health Center - New Haven
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06609369
The ClinicalTrials.gov registry entry for NCT06609369 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 169-participant average among 151 other Insomnia trials with a reported enrollment target (33% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Experimental health intervention is the first listed.
NCT06609369 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06609369 about?
NCT06609369 is a clinical study titled "Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse". The study aims to investigate whether behavioral interventions promote cessation in adult smokers by ameliorating negative emotions and improving self-control and identify the neural markers of these effects.
What is the current status of trial NCT06609369?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2025-04-21. Estimated completion is 2029-06.
What conditions does trial NCT06609369 study?
This clinical trial studies the following conditions: Insomnia, Tobacco Use, Tobacco Cessation.
What interventions are being tested in trial NCT06609369?
The interventions under investigation include: Experimental health intervention (BEHAVIORAL), Varenicline (DRUG).
Who is sponsoring clinical trial NCT06609369?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06609369 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Pimavanserin for Insomnia in Veterans With PTSD
RECRUITING · Phase 2
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Suvorexant for Treatment of AUD and PTSD
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
-
Resilience Enhancement Following Sleep Treatment
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.